Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma

Abstract

Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss of functional von Hippel–Lindau (VHL) protein and high, homogeneous expression of the G250MN protein, an isoenzyme of the carbonic anhydrase family. High expression of G250MN is found in all ccRCCs, but not in most normal tissues, including normal human kidney. We specifically studied the mechanism of transcriptional regulation of the CAIXG250 gene in RCC. Previous studies identified Sp1 and hypoxia-inducible factor (HIF) as main regulatory transcription factors of G250MN in various non-RCC backgrounds. However, G250MN regulation in RCC has not been studied and may be differently regulated in view of the HIF accumulation under normoxic conditions due to VHL mutations. Transient transfection of different G250MN promoter constructs revealed strong promoter activity in G250MN -positive RCC cell lines, but no activity in G250MN -negative cell lines. DNase-I footprint and band-shift analysis demonstrated that Sp1 and HIF-1α proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX promoter activity, indicating their critical importance for the activation of G250 expression in RCC. A close correlation between HIF-1α expression and G250MN expression was observed. In contrast, no relationship between HIF-2α expression and G250MN was seen. The participation of cofactor CBP/p300 in the regulation of G250 transcription was shown. In conclusion, HIF-1α and Sp1, in combination with CBP/p300, are crucial elements for G250MN expression in ccRCC, and CAIXG250 can be regarded as a unique HIF-1α target gene in ccRCC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

CAIX:

G250 gene

ccRCC:

clear cell renal cell carcinoma

EMSA:

electrophoretic mobility shift assay

G250:

G250CAIX/MN

HIF:

hypoxia-inducible factor

HGH:

human growth hormone

HRE:

hypoxia-responsive element

HSV-tk:

herpes simplex virus-thymidine kinase

NE:

nuclear extract

PCR:

polymerase chain reaction

TF:

transcription factor

VHL:

von Hippel–Lindau

References

  • Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF and Livingston DM . (1996). Proc. Natl. Acad. Sci. USA, 93, 12969–12973.

  • Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P and Harris AL . (2001). Cancer Res., 61, 5262–5267.

  • Bockamp EO, Fordham JL, Gottgens B, Murrell AM, Sanchez MJ and Green AR . (1998). J. Biol. Chem., 273, 29032–29042.

  • Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA and Belldegrun AS . (2003). Clin. Cancer Res., 9, 802–811.

  • Carrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H and Poellinger L . (2000). Mol. Cell. Biol., 20, 402–415.

  • Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ and Maher ER . (2001). Oncogene, 20, 5067–5074.

  • Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ . (1990). Cancer Res., 50, 5531–5536.

  • Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G and Flamme I . (2003). J. Biol. Chem., 278, 7520–7530.

  • Gothie E, Richard DE, Berra E, Pages G and Pouyssegur J . (2000). J. Biol. Chem., 275, 6922–6927.

  • Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ and Oosterwijk E . (2000). Int. J. Cancer, 85, 865–870.

  • Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM . (1994). Proc. Natl. Acad. Sci. USA, 91, 9700–9704.

  • Hu CJ, Wang LY, Chodosh LA, Keith B and Simon MC . (2003). Mol. Cell. Biol., 23, 9361–9374.

  • Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI and Stanbridge EJ . (2001). Am. J. Pathol., 158, 905–919.

  • Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA and van der Kogel AJ . (2002). Cancer Res., 62, 7066–7074.

  • Kaluzova M, Pastorekova S, Svastova E, Pastorek J, Stanbridge EJ and Kaluz S . (2001). Biochem. J., 359, 669–677.

  • Kaluz S, Kaluzova M, Opavsky R, Pastorekova S, Gibadulinova A, Dequiedt F, Kettmann R and Pastorek J . (1999). J. Biol. Chem., 274, 32588–32595.

  • Kaluz S, Kaluzova M and Stanbridge EJ . (2003). Cancer Res., 63, 917–922.

  • Liu Z and Simpson ER . (1999). Mol. Cell. Endocrinol., 153, 183–196.

  • Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ and West CM . (2001). Cancer Res., 61, 6394–6399.

  • Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ and Maxwell PH . (2002). Cancer Cell, 1, 459–468.

  • Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER and Latif F . (2000). Mol. Pathol., 53, 137–144.

  • Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ . (1999). Nature, 399, 271–275.

  • Michel G, Minet E, Mottet D, Remacle J and Michiels C . (2002). Biochim. Biophys. Acta, 1578, 73–83.

  • Motzer RJ, Bander NH and Nanus DM . (1996). N. Engl. J. Med., 335, 865–875.

  • Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J and Warnaar SO . (1986). Int. J. Cancer, 38, 489–494.

  • Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R and Pastorek J . (1996). Genomics, 33, 480–487.

  • Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S and Eckardt KU . (2002). J. Am. Soc. Nephrol., 13, 1721–1732.

  • Sambrook J and Russell DW . (2001). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.

    Google Scholar 

  • Sang N, Fang J, Srinivas V, Leshchinsky I and Caro J . (2002). Mol. Cell. Biol., 22, 2984–2992.

  • Suzuki T, Kimura A, Nagai R and Horikoshi M . (2000). Genes Cells, 5, 29–41.

  • Thrash-Bingham CA and Tartof KD . (1999). J. Natl. Cancer Inst., 91, 143–151.

  • Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y and Oosterwijk E . (1999). Br. J. Cancer, 81, 741–746.

  • Verhaegh GW, Van Bokhoven A, Smit F, Schalken JA and Bussemakers MJ . (2000). J. Biol. Chem., 275, 37496–37503.

  • Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, Debruyne FM and Schalken JA . (1998). Am. J. Clin. Pathol., 110, 647–652.

  • Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U, Maher ER, Grone HJ and Eckardt KU . (2001). Cancer Res., 61, 5215–5222.

  • Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL . (2000). Cancer Res., 60, 7075–7083.

Download references

Acknowledgements

This work was supported by a grant from the Dutch Cancer Society (Grant no. KUN 96-1345). EO was supported by the Ludwig Institute for Cancer Research, New York.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Egbert Oosterwijk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grabmaier, K., de Weijert, M., Verhaegh, G. et al. Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma. Oncogene 23, 5624–5631 (2004). https://doi.org/10.1038/sj.onc.1207764

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207764

Keywords

This article is cited by

Search

Quick links